GL0034 (Utreglutide), a long acting, glucagon-like peptide-1 receptor agonist, improves body weight loss, lipid and liver injury markers in individuals with obesity: A phase 1 multiple ascending dose study

被引：0
|
作者：
Thennati, Rajamannar [1 ]
Burade, Vinod [1 ]
Natarajan, Muthukumaran [1 ]
Shahi, Pradeep [1 ]
Nagaraja, Ravishankara [1 ]
Agrawal, Sudeep [1 ]
Jandrain, Bernard [2 ,3 ]
Duvauchelle, Thierry [4 ]
Pratley, Richard E. [5 ]
Thorens, Bernard [6 ]
Vilsboll, Tina [7 ]
Loomba, Rohit [8 ]
机构：
[1] Sun Pharmaceut Ind Ltd, High Impact Innovat Sustainable Hlth Solut HISH, Vadodara, India
[2] Acad Hosp Liege, Clin Pharmacol Unit, ATC Co, Liege, Belgium
[3] Acad Hosp Liege, Div Diabet Nutr & Metab Disorders, Liege, Belgium
[4] Phaster1, Paris, France
[5] AdventHealth Translat Res Inst, Orlando, FL USA
[6] Univ Lausanne, Ctr Integrat Genom, Lausanne, Switzerland
[7] Univ Copenhagen, Steno Diabet Ctr Copenhagen, Clin Res, Copenhagen, Denmark
[8] Univ Calif San Diego, Sch Med, La Jolla, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT-231
引用
收藏
页码：S615 / S616
页数：2
相关论文
共 49 条
  • [31] Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes
    Pratt, Edward
    Ma, Xiaosu
    Liu, Rong
    Robins, Deborah
    Coskun, Tamer
    Sloop, Kyle W. W.
    Haupt, Axel
    Benson, Charles
    DIABETES OBESITY & METABOLISM, 2023, 25 (09): : 2642 - 2649
  • [32] Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study
    Amin, Neeta B.
    Frederich, Robert
    Tsamandouras, Nikolaos
    Haggag, Amina Z.
    Schuster, Tilman
    Zmuda, Witold
    Palmer, Alexandra
    Vasas, Szilard
    Buckley, Gina
    Smith, Timothy R.
    Dubrava, Sarah J.
    Zhu, Qi
    Johnson, Margot
    DIABETES OBESITY & METABOLISM, 2025, 27 (01): : 215 - 227
  • [33] Unexpected cardiovascular risks of glucagon-like peptide-1 receptor agonist and aspirin co-administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study
    Lin, Chia-Ming
    Chen, Jo-Ching
    Meyerowitz-Katz, Gideon
    Huang, Yu-Nan
    Su, Pen-Hua
    DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 1980 - 1991
  • [34] Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study
    Hurtado, Isabel
    Robles, Celia
    Peiro, Salvador
    Garcia-Sempere, Anibal
    Sanfelix-Gimeno, Gabriel
    DIABETOLOGIA, 2024, 67 (11) : 2471 - 2480
  • [35] In Women with Prior Gestational Diabetes Mellitus, the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Improves Glucose Tolerance Irrespective of Body Weight Loss after Five Years of Treatment, but Effects Are Lost after Wash-Out
    Andersen, Emilie S.
    Foghsgaard, Signe
    Vedtofte, Louise
    Pedersen, Marie H.
    Forman, Julie
    Mathiesen, Elisabeth R.
    Svare, Jens
    Holst, Jens J.
    Clausen, Tine D.
    Damm, Peter
    Knop, Filip K.
    Vilsboll, Tina
    DIABETES, 2021, 70
  • [36] Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
    Vilsboll, Tina
    Zdravkovic, Milan
    Le-Thi, Tu
    Krarup, Thure
    Schmitz, Ole
    Courreges, Jean-Pierre
    Verhoeven, Robert
    Buganova, Ingrid
    Madsbad, Sten
    DIABETES CARE, 2007, 30 (06) : 1608 - 1610
  • [37] A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
    Jensterle, Mojca
    Kravos, Nika Aleksandra
    Pfeifer, Marija
    Kocjan, Tomaz
    Janez, Andrej
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2015, 14 (01): : 81 - 90
  • [38] A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
    Mojca Jensterle
    Nika Aleksandra Kravos
    Marija Pfeifer
    Tomaz Kocjan
    Andrej Janez
    Hormones, 2015, 14 : 81 - 90
  • [39] Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis
    Yuan, Xia
    Gao, Zhe
    Hao, Zhihua
    Ma, Huijuan
    Duan, Kaixin
    Yang, Caixuan
    MEDICINE, 2023, 102 (43)
  • [40] Effectiveness and care continuity in an app-based, glucagon-like peptide-1 receptor agonist-supported weight-loss service for women with overweight and obesity in the UK: A real-world retrospective cohort analysis
    Talay, Louis
    Vickers, Matt
    DIABETES OBESITY & METABOLISM, 2024, 26 (07): : 2984 - 2987
12345